logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

InduPro raised $85 million in a Series A financing co-led by The Column Group and Vida Ventures to advance next-generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Disease.

Jun 13, 2024•over 1 year ago

Amount Raised

$85 Million

Round Type

series a

SeattleTherapeuticsBiotechnologyHealth Care

Investors

Euclidean CapitalEmerson CollectiveMrl Ventures FundVida VenturesThe Column Group

Description

InduPro, a biotechnology company, announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund, Emerson Collective, and Euclidean Capital. The funding will support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs and fuel a pipeline of novel bispecific antibodies and antibody drug conjugates.

Company Information

Company

InduPro

Location

Seattle, Washington, United States

About

InduPro, Inc. is a biotechnology company that defines protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases. They target cell surface proteins in a variety of disease contexts by leveraging inherent or induced protein proximity. Their approach relies on a unique discovery engine (ProXiMATE) to generate potential first-in-class and best-in-class novel therapeutic candidates across multiple indications and modalities.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech